CN110022874A - 以tpcs-2a诱导的吉西他滨光化学内在化治疗胆管癌 - Google Patents

以tpcs-2a诱导的吉西他滨光化学内在化治疗胆管癌 Download PDF

Info

Publication number
CN110022874A
CN110022874A CN201780073846.XA CN201780073846A CN110022874A CN 110022874 A CN110022874 A CN 110022874A CN 201780073846 A CN201780073846 A CN 201780073846A CN 110022874 A CN110022874 A CN 110022874A
Authority
CN
China
Prior art keywords
gemcitabine
cytotoxic agent
tpcs
dose
administered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201780073846.XA
Other languages
English (en)
Chinese (zh)
Inventor
A·霍盖斯特
P·E·威尔戴
P·K·塞尔博
K·艾文德维克
L·费尼桑德
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
PCI Biotech AS
Original Assignee
PCI Biotech AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB1617526.7A external-priority patent/GB201617526D0/en
Priority claimed from GBGB1704719.2A external-priority patent/GB201704719D0/en
Application filed by PCI Biotech AS filed Critical PCI Biotech AS
Publication of CN110022874A publication Critical patent/CN110022874A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/409—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having four such rings, e.g. porphine derivatives, bilirubin, biliverdine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
    • A61K41/0071—PDT with porphyrins having exactly 20 ring atoms, i.e. based on the non-expanded tetrapyrrolic ring system, e.g. bacteriochlorin, chlorin-e6, or phthalocyanines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201780073846.XA 2016-10-14 2017-10-13 以tpcs-2a诱导的吉西他滨光化学内在化治疗胆管癌 Pending CN110022874A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GBGB1617526.7A GB201617526D0 (en) 2016-10-14 2016-10-14 Method
GB1617526.7 2016-10-14
GBGB1704719.2A GB201704719D0 (en) 2017-03-24 2017-03-24 Method
GB1704719.2 2017-03-24
PCT/EP2017/076257 WO2018069536A1 (en) 2016-10-14 2017-10-13 Treatment of cholangiocarcinoma with tpcs-2a induced photochemical internalisation of gemcitabine

Publications (1)

Publication Number Publication Date
CN110022874A true CN110022874A (zh) 2019-07-16

Family

ID=60186250

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201780073846.XA Pending CN110022874A (zh) 2016-10-14 2017-10-13 以tpcs-2a诱导的吉西他滨光化学内在化治疗胆管癌

Country Status (13)

Country Link
US (1) US20200338044A1 (https=)
EP (1) EP3525783B1 (https=)
JP (1) JP2019530718A (https=)
KR (1) KR20190068573A (https=)
CN (1) CN110022874A (https=)
AU (1) AU2017342086A1 (https=)
CA (1) CA3040344A1 (https=)
DK (1) DK3525783T3 (https=)
ES (1) ES2841941T3 (https=)
PL (1) PL3525783T3 (https=)
RU (1) RU2019109682A (https=)
SG (1) SG11201903057XA (https=)
WO (1) WO2018069536A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201913124D0 (en) * 2019-09-11 2019-10-23 Seald As Compositions and methods for treatment of cholangiocarcinoma
GB201913121D0 (en) * 2019-09-11 2019-10-23 Seald As Compositions and methods for treatment of cholangiocarcinoma
GB202301312D0 (en) 2023-01-30 2023-03-15 Pci Biotech As Method and product

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NO180167C (no) 1994-09-08 1997-02-26 Photocure As Fotokjemisk fremgangsmåte til å innföre molekyler i cellers cytosol
GB9905911D0 (en) 1999-03-15 1999-05-05 Photocure As Method
PT1346059E (pt) 2000-11-29 2012-06-01 Pci Biotech As Internalização fotoquímica para distribuição de moléculas no citosol
GB0121023D0 (en) * 2001-08-30 2001-10-24 Norwegian Radium Hospital Res Compound
GB0914286D0 (en) * 2009-08-14 2009-09-30 Pci Biotech As Method
GB0914287D0 (en) * 2009-08-14 2009-09-30 Pci Biotech As Compositions

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
ALEJANDRA MARTINEZ DE PINILLOS BAYONA等: "Enhancing the efficacy of cytotoxic agents for cancer therapy using photochemical internalisation", 《INTERNATIONAL JOURNAL OF CANCER》 *
PCI BIOTECH AS: "A Phase I/II Study Safety and Efficacy Study of PCI of Gemcitabine and Chemotherapy in Patients With Cholangiocarcinomas", 《网络公开HTTPS://CLINICALTRIALS.GOV/CT2/HISTORY/NCT01900158?V_6=VIEW#STUDYPAGETOP》 *
高源等: "光敏剂在癌症诊断和治疗中的研究进展", 《分析化学》 *

Also Published As

Publication number Publication date
CA3040344A1 (en) 2018-04-19
WO2018069536A1 (en) 2018-04-19
RU2019109682A3 (https=) 2021-02-15
EP3525783B1 (en) 2020-12-16
DK3525783T3 (da) 2021-01-18
JP2019530718A (ja) 2019-10-24
RU2019109682A (ru) 2020-11-16
AU2017342086A1 (en) 2019-05-09
EP3525783A1 (en) 2019-08-21
US20200338044A1 (en) 2020-10-29
PL3525783T3 (pl) 2021-04-19
ES2841941T3 (es) 2021-07-12
KR20190068573A (ko) 2019-06-18
SG11201903057XA (en) 2019-05-30

Similar Documents

Publication Publication Date Title
Aebisher et al. The use of photodynamic therapy in medical practice
Spring et al. The role of photodynamic therapy in overcoming cancer drug resistance
Zelefsky et al. Prophylactic sildenafil citrate improves select aspects of sexual function in men treated with radiotherapy for prostate cancer
Huggett et al. Phase I/II study of verteporfin photodynamic therapy in locally advanced pancreatic cancer
Higgins et al. Drug radiotherapy combinations: review of previous failures and reasons for future optimism
JP2002534219A (ja) 標的細胞の経皮的な光力学的処置
Paraboschi et al. Near-InfraRed PhotoImmunoTherapy (NIR-PIT) for the local control of solid cancers: Challenges and potentials for human applications
Zhang et al. Hyaluronate-based self-stabilized nanoparticles for immunosuppression reversion and immunochemotherapy in osteosarcoma treatment
JP2023018029A (ja) 癌の処置のための医薬組成物および方法
CN110022874A (zh) 以tpcs-2a诱导的吉西他滨光化学内在化治疗胆管癌
JP5802198B2 (ja) 経口投与のための新規の光増感剤製剤
Suntharalingam et al. The evaluation of amifostine for mucosal protection in patients with advanced loco-regional squamous cell carcinomas of the head and neck (SCCHN) treated with concurrent weekly carboplatin, paclitaxel, and daily radiotherapy (RT)
EP2296706A2 (en) Photochemical internalisation of kinase inhibitors
Xiong et al. Comparative study of two kinds of repeated photodynamic therapy strategies in breast cancer by using a sensitizer, sinoporphyrin sodium
Wirth et al. Strategies to improve drug delivery in bladder cancer therapy
JP2020503322A (ja) 低線量放射線を織り込んで用いることによる化学療法による損傷の減少および癌の死滅率の上昇
Biel Clinical photodynamic therapy: The evolution of photodynamic therapy treatment of head and neck cancer
Abrams et al. Update on glioma biotechnology
JP2016034927A (ja) 高密度焦点式超音波治療法と抗癌剤療法との併用療法に用いる抗癌剤
Istomin et al. Photodynamic therapy with photosensitizer photolon for oral leukoplakia
Waters et al. New Approaches to the Treatment of Gastro-lntestinal Cancer
RU2524309C1 (ru) Способ выбора тактики лечения местно-распространенного рака предстательной железы
KR20120018234A (ko) Ｐｄｔ를 이용한, 포유동물의 종양 또는 피부질환 치료방법
RU2853399C1 (ru) Способ повышения эффективности радиотерапии солидных новообразований в эксперименте
ES3017257T3 (en) Abt-751 and ionizing radiation for use in treating a brain tumor

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20190716

WD01 Invention patent application deemed withdrawn after publication